Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression

Leena Arora and Durba Pal*

Tissue Engineering and Regenerative Medicine Lab, Indian Institute of Technology Ropar, Rupnagar, India

The molecular understanding of carcinogenesis and tumor progression rests in intra and inter-tumoral heterogeneity. Solid tumors confined with vast diversity of genetic abnormalities, epigenetic modifications, and environmental cues that differ at each stage from tumor initiation, progression, and metastasis. Complexity within tumors studied by conventional molecular techniques fails to identify different subclasses in stromal and immune cells in individuals and that affects immunotherapies. Here we focus on diversity of stromal cell population and immune inhabitants, whose subtypes create the complexity of tumor microenvironment (TME), leading primary tumors towards advanced-stage cancers. Recent advances in single-cell sequencing (epitope profiling) approach circumscribes phenotypic markers, molecular pathways, and evolutionary trajectories of an individual cell. We discussed the current knowledge of stromal and immune cell subclasses at different stages of cancer development with the regulatory role of non-coding RNAs. Finally, we reported the current therapeutic options in immunotherapies, advances in therapies targeting heterogeneity, and possible outcomes.

Keywords: tumor microenvironment, stromal cell, immune cell, tumor progression, non-coding RNAs

INTRODUCTION

“What is it that determines what organs shall suffer in the case of disseminated cancer”? (1). The answer to this question proposed by Stephan Paget way back in 1889 led oncologists to study different perspectives of growing tumors. Oncology is now branched to multiple disciplines starting from early studies on genomic alterations, chromosomal aberrations, altered signaling, and cell plasticity. Cancers are more than “just a disease of the genome” and hint clinicians to study various aspects of tumor biology. During development, cancer cells undergo stochastic genetic and epigenetic alterations leading to molecular and phenotypic differences that have implications in heterogeneity, forcing the construction of their niche (2). Tumors have multiple non-cancerous regenerative cell types that eventually differentiate into various tumor supporting cells (3). Lineage plasticity enables cancer cells to adapt to changing environmental conditions like aberrant
vascularity, low oxygen tension, high metabolic rates, and low pH. It is the ability of a non-cancerous/cancerous cell to differentiate into other cell types of distinct lineage (4). Embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and adult stem cells (ADCs) within the TME define routes to cell plasticity and are the known originators of other cell types like cancer-associated fibroblasts (CAF), tumor endothelial cells (TECs), tumor-associated macrophages (TAM) to name a few. These stem cells have the potential to differentiate into a broad spectrum of cell types; however, the activation of pathways that control stem cell is poorly understood (5). Studies on ESCs and pathway analysis would help us to understand the developmental plasticity in TME. Development of fundamental methods to understand the role of ESCs in tumors include a) development of organoid models from patient-derived samples, b) culture of ESCs in the artificial stromal environment, and c) study of activation pathways that derive stem cell characteristics. Tumor organoids lead cancer research to study stromal and immune cell interaction in TME but have certain limitations. Patient-derived tumor organoids do not always recreate tumor tissue architecture as they are anchorage-dependent (requires basement membrane). The addition of extracellular matrix may not be a passive bystander, but the biological consequences of this are unexplored. Phenotypic and genotypic variations from organoid to organoid may affect the experimental reproducibility and enhance false-positive results. Potential contaminants like normal epithelial cells cannot be ignored and hence affect pathway studies in tumors. Lineage-specific transcription factors that are known to govern embryonic cell fate specifications also plays a role in characterizing cancer subtypes (6).

There are several mechanisms of cellular plasticity. Differentiation is the most common route by which a pluripotent stem cell evolves into a mature cell type (7). Contrarily, de-differentiation reverts the terminally differentiated cancer cells to a less differentiated stage within its lineage. Trans-differentiation is another such route that takes de-differentiation a step further to a point where it delineates and differentiates to other cell types (8). Reprogramming is a different mechanism where a differentiated cell reverts to its pluripotent source to adapt to any other cell type (9). Reprogramming is a less explored area in TME but has a huge potential in regenerative medicine. It outlines the structure for establishing different cell types and promotes the development of stromal cells like epithelial cells, CAFs, TECs, pericytes, and immune cells, including monocytes, TAMs, neutrophils, NK cells, B cells, T cells (10). These cell types also differ phenotypically and genetically as the tumor progresses to advanced stage (11).

Non-coding RNAs function as significant players in post-transcriptional gene regulation within diverse cell types. Cancers are primarily regulated by a different set of non-coding RNAs, classified according to their sizes (12). MicroRNAs (miRNAs), piwi-interacting RNAs (piRNAs), and small interfering RNAs (siRNAs) are generated from precursor molecules. Long non-coding RNAs (lncRNAs) are higher than 200 nucleotides in length produced from intergenic regions. Circular RNAs (circRNAs) are a class of lncRNAs generated by a process called back-splicing, wherein downstream exons are spliced to upstream exons in the reverse order that acts as miRNA sponges as well (13). Increased sequencing depth and RNA profiling strategies have identified varied sets of non-coding RNAs including large intergenic non-coding RNAs (lincRNAs), intron-derived small nucleolar lincRNAs ( sno-lincRNAs), enhancer RNAs (eRNAs), along with already known miRNAs, piRNAs, however, functional roles of many are still unknown in cancers (14). miRNAs, lncRNAs, and circRNAs regulate cancer stem cell characteristics, epithelial-mesenchymal transitions (EMTs), and vice-versa by epigenetic and transcriptional modification (15).

The role of non-coding RNA players in regulating stromal and immune cell diversity within TME is specified in the respective sections.

**STROMAL CELL HETEROGENEITY**

TME is remarkably a complex ecosystem with a heterogeneous population of cancer cells and the associated stroma, which drives tumor initiation and growth. Stromal cells, extracellular matrix, paracrine signaling molecules (chemokines, cytokines, and growth factors), and immune landscape formulates TME (16). Interactions within genetically altered cancer cells and stromal cells regulate hallmarks of cancer, such as replicative potentiality, sustained angiogenesis, invasion, and metastasis (17). Understanding cell heterogeneity in TME determines which stromal cells have the potential to contribute to tumor development and progression (18). Intra-tumoral heterogeneity within varied tumor types clinically fails/minimally adopts the given therapeutics and is one of the critical reasons for post-treatment immune-modulatory microenvironment and tumor relapse. Therefore, understanding each component and related phenotypic distinctions of this stromal population would help to predict the difference in primary and advanced tumor cell subtypes, genomic co-relations within subtypes, population-specific markers, molecular/cellular pathways governing developmental origins and differentiation, the source of antitumor/inflammatory cells, and modifiers of immune microenvironment. Stromal cells are comparatively fewer than epithelial and immune cells (19). Single-cell RNA sequencing (scRNAseq) gives a comprehensive blueprint of stromal and immune cell subtypes and analyses differentiation dynamics. It identifies rare cell populations and transcriptome responses in specific tumor conditions in individual or collective tumor samples. Advances in this technology enable studies on genetic and non-genetic tumor mechanisms, microenvironmental cues, cell-cell interactions, developmental pathways, rare tumor subpopulations, and investigation of non-responders to cancer treatments (20). Not only for tumor assessments, but single-cell sequencing is also beneficial for developing next-generation cell-based therapies. Its efficiency in providing high-resolution genome-wide molecular readouts allows the characterization of tumor samples at a larger scale, identifying new targets for drug development based on repressed or activated gene expressions (21).
DIVERSITY IN TUMOR REMODELING: CAFs AND DISTINCT GENE PROGRAMS

CAFs are the major stromal component of many solid tumors and are well-known phenotypic remodelers of the stromal environment (22). They constitute a diverse cell population, but the extent of heterogeneity is scarcely explored. Based on different expression signatures, fibroblasts are subdivided into 1) Quiescent fibroblasts: less tumorigenic and primarily found in non-malignant samples and 2) myofibroblasts/CAFs that promote tumors causing tumor resistance, relapse, and strongly enriched in malignant or metastatic tumors (23). They secrete a unique repertoire of collagens and elastins, maintaining the extracellular matrix, thus characterizes desmoplasic (23). Quiescent fibroblasts secrete low levels of collagens, specifically COL13A1 and COL14A1 and high levels of elastins. Myofibroblasts exclusively originate from tumor tissues and are mostly enriched in collagens and low elastins (24). Myofibroblast subtypes have different activation mechanisms such as TGF-β1, IL-11 stimulation, and IL-1β. IL-6 treatment that induces upregulation of inflammatory fibroblast marker genes (iCAFs) (25). CAF specific markers of identification include α smooth muscle actin (αSMA) (also known as ACTA2), desmin, S100A4, Fibroblast activated protein (FAP), express pro-inflammatory cytokine arrays like IL-1β, IL-6, IL-8, TGF-β, CXCL12, and collagen (18). Fibroblastic reticular cells are another immunologically specialized myofibroblasts that are known to attract immune cells within lymph nodes. These fibroblasts generate ECM for the transit of potential antigens, serve as a migration pathway for leukocytes allowing active immune surveillance (26). CAFs are further characterized based on distinct cellular sources: vascular CAFs (vCAFs), matrix CAFs (mCAFs), cycling CAFs (cCAFs) and developmental CAFs (dCAFs). vCAFs originate from perivascular areas, mCAFs and dCAFs are the product of resident fibroblasts found in TME of genetically engineered MMTV-PyMT mouse model of breast cancer (27).

Differentiation to CAFs and Its Subtypes

Diversity in Tumor Remodeling

Arora and Pal Cell Diversity in Tumor Microenvironment

Endothelial cells are in a constant mode of activation, quiescence, and re-activation, depending on the growing tumors’ metabolic needs and requirements (42). Individual endothelial cells adopt different phenotypes and functions according to the tumor requirements. Endothelial cell phenotypes are primarily divided into tip cells and stalk cells that exhibit distinct genotypes (42). With advances in technologies and the advent of scRNA seq techniques, different subpopulations are discovered. The first parameter to distinguish ECs from the rest of the tumor cells is a separation through a pan-hematopoietic marker (CD45−) combined with CD31, CD144, and vWF. CD31 is a transmembrane glycoprotein that forms the intercellular junctions, CD144 (VE-Cadherin) is an endothelial adhesion molecule and vWF (von Willebrand Factor), a glycoprotein that mediates platelet adhesion in the endothelium (43). All these are preliminary markers to separate endothelial cell

Non-Coding RNAs Involved in Fibroblast Differentiation to CAFs and Its Subtypes

Despite being highly researched, CAFs are still a mystery and can be a great tumor-targeting cell if explored. It is a dynamic population in TME that is pluripotent and is known for differentiating into other cell types. Various reviews have highlighted the miRNAs involved in fibroblast differentiation, tumor progression, and metastasis (12, 22). In breast, ovarian, and endometrial cancers downregulation of mir-31, mir-214, mir-148a, mir-205, mir-200b, mir-200c, mir-141, mir-101, mir-342-3p, let-7g, mir-26b, mir-15a, mir-16, and upregulation of mir-155, mir-221-5p, mir-221-3p miRNAs have shown significant regulation in the tumor microenvironment. Reversal of these microRNAs reversed the CAFs’ phenotypic and genotypic characteristics (35). Recently identified non-coding RNAs miR877-3p, and mir-133a targets TGF-β axis causing myofibroblast differentiation (36, 37). Twist1 induced mir-199a-3p suppress caveolin-2 and activates myofibroblast differentiation via TGF-β pathway (38). LncRNAs further plays a significant role in determining fibroblast subtypes. LINC0092 long non-coding RNA upregulation is co-related with CXCL14-mediated CAF progression in ovarian cancer cells. LINC0092 overexpression is related to poor clinical prognosis and increased glycolysis leading to metastasis (39). Tong and co-workers discovered the role of exosomal IncRNA POU3F3 in esophageal squamous cell carcinoma (ESCC). POU3F3 regulates fibroblast differentiation to CAFs and causes cisplatin resistance in ESCC. Many IncRNAs with similar roles in different cancers are known: ASC9, PART1, CCAT1, TTN-AS1, DNM3OS, FMRI-AS1, LINC01419, NMR, PCAT1, ROR (40). Aberrant circRNA expression is co-related with myofibroblast differentiation and tumorigenesis. circHIPK3 regulates lung fibroblast-to-myofibroblast transition by functioning as a competing endogenous RNA. circHIPK3 functions as an endogenous mir-338-3p sponge and inhibit miR-338-3p activity, increasing SOX4 and COL1A1 expression and fibroblast differentiation (41). Advances in recent research and use of circRNA databases (for example, MiOncoCirc) are required further to identify the role of circRNA in cellular plasticity variations and using them as therapeutic options.

PROFILING OF PHENOTYPICALLY ABNORMAL TUMOR ENDOTHELIAL CELLS

Endothelial cells are in a constant mode of activation, quiescence, and re-activation, depending on the growing tumors’ metabolic needs and requirements (42). Individual endothelial cells adopt different phenotypes and functions according to the tumor requirements. Endothelial cell phenotypes are primarily divided into tip cells and stalk cells that exhibit distinct genotypes (42). With advances in technologies and the advent of scRNA seq techniques, different subpopulations are discovered. The first parameter to distinguish ECs from the rest of the tumor cells is a separation through a pan-hematopoietic marker (CD45−) combined with CD31, CD144, and vWF. CD31 is a transmembrane glycoprotein that forms the intercellular junctions, CD144 (VE-Cadherin) is an endothelial adhesion molecule and vWF (von Willebrand Factor), a glycoprotein that mediates platelet adhesion in the endothelium (43). All these are preliminary markers to separate endothelial cell
population. Other EC identification markers include tip genes (ESM1, NID2, KCNE3, DLL4, RAMP3, EDNRB, CLDN5), capillary markers (CA4, CD36), ACKR1 gene expression by high endothelial venules, arterial (FBLN5, GJA5), lymphatic markers (PROX1, PDPN), pericyte marker RGS5, non-myeloid specific marker AIF1 in different cancer types (44). Stalk endothelial cells generally express VWF, SELP, ACKR, and TMEM252. Several pro-angiogenic factors, metabolic signatures, and transcription factors have differential expression in tumor endothelial cells compared to non-tumor cells like HSFG2 (44). Lambrechts and co-workers classified tumor endothelial cells in different clusters based on the marker genes identified: Lymphatic endothelial cells (PDPN+, PROX1+), tumor-derived blood endothelial cells (FLT1+, IGFBP3+, and SPRY1+), malignant, and non-malignant endothelial cells (23) (Figure 1). Transcriptional and epigenetic dysregulation in TME triggers the formation of these angiogenic candidates and their subtypes from healthy blood endothelial cells. TEC subtypes lead to loss of vascular integrity, structure fragile and leaky blood vessels, and migration of immune cells, thus contributing to the growing complexity of tumors (45). Goveia and co-workers extend the endothelial heterogeneity by discovering previously unknown functionally validated endothelial phenotypes across patients and in-vitro/in-vivo models. Non-malignant lung (hpNECs) tissues have a comparatively high abundance of postcapillary, alveolar type II, scavenging, and lymphatics endothelial cells than aggressive tumors. TEC phenotypes were majorly immature ECs, tip cells, patient-specific and lymphatics hTECs. Arterial, activated postcapillary veins, and alveolar type II phenotypes are common in non-tumor and tumor tissues (46). They have also identified top-ranked markers of each phenotype and specified roles in tumor progression (listed in Table 2). The top-ranked marker genes have significant roles in regulating immune surveillance, EC migration, matrix remodeling, VEGF signaling, and angiogenesis by increasing growth factors and chemical stimuli that triggers angiogenic cascade within TME, including vascular endothelial growth factor (VEGF),
# TABLE 1 | Cancer-associated fibroblast subtypes found in tumor tissues as revealed by single cell RNA sequencing.

| Cancer type/models | CAF subtypes | Markers/gene signature | Significance | References |
|--------------------|--------------|------------------------|--------------|-----------|
| Lung adenocarcinoma | Matrix fibroblasts | COL13A1+, COL14A1+ | Present majorly in early-stage tumor tissues | (30, 31) |
|                    | Fibroblastic reticular cells | PDPN, PDGFRα | Immunologically specialized myofibroblasts that gather immune cells into the lymph node, support T cell, and B cell survival but prevent their activation, maintains dendritic cell migration | (32) |
| PDAC (Human+Mouse) | Myofibroblasts | α-SMA++, TAGLN, MYL9, TPM1, TPM2, MMP11, POSTN, HOPX (contractile proteins) | Found primarily adjacent to the cancer cells, Smooth muscle contraction, focal adhesion, ECM organization, collagen formation | (32) |
|                    | Inflammatory CAFs (ICAFs) | CLEC3B, PDGFRα, CFD, LMNA, DPT, AGTR1, HAS1, HAS2 (matrix proteins) | Found in desmoplastic areas away from tumors, activate inflammatory pathways such as IFNγ response, TNF-α/IL6/STAT3, IL6/JAK/STAT3, and the complement pathway | (32) |
| PDAC (Human) | Antigen-presenting CAFs (apICAFs) | COL1A1, COL1A2, DCN, PDPN, MHCII genes (HLA-DRA, HLA-DPA1, and HLA-DQA), CD74 | Have immunomodulatory capacity (activate CD4+ T cells), involved in antigen presentation and processing, fatty-acid metabolism, MYC targets, and MTORC1 signaling | (28, 29) |
| Breast Cancer | Lipofibroblasts | FABP4, CAR3 | Lipid droplet-containing fibroblasts, express lipid metabolism genes | (33) |
| Breast Cancer | CAF-S1 | CD29⁺ FAP⁺⁺ FSP1⁺⁺ αSMA⁺⁺ PDGFRβ⁺⁻ CAV1low | Key player in immunosuppression, promote differentiation of CD4+CD25+ T lymphocytes into CD25+FOXP3+ cells, characterized by cell adhesion, ECM organization, and immune response | (33) |
| Breast Cancer | CAF-S2 | CD29⁺⁺⁺ FAP⁺⁺ FSP1⁺⁺ αSMA⁺⁺ PDGFRβ⁺⁻ CAV1low | Mainly present in LumA tumors | (33) |
| Breast Cancer | CAF-S3 | CD29⁺⁺⁺ FAP⁺⁺ FSP1⁺⁺ αSMA⁺⁺ PDGFRβ⁺⁻ CAV1low | Detected mainly in juxta-tumors | (33) |
| Breast Cancer | CAF-S4 | CD29⁺⁺⁺ FAP⁺⁺ FSP1⁺⁺ αSMA⁺⁺ PDGFRβ⁺⁻ CAV1low | Activated CAF subset, detected in all tumor types LumA, TNBC, HER2, characterized by muscle contraction, regulation of actin cytoskeleton, and oxidative metabolism | (33) |
| Breast Cancer (MMTV-PyMTmouse model) | Vascular CAFs (vCAFs) | vascular regulatory genes (NOTCH3, EPAS1, COL18A1, NR2F2), desmin, Nidogen-2 | Originated from perivascular location, significant role in vascular development and angiogenesis | (27) |
|                    | Matrix CAFs (mCAFs) | ECM-related genes (DCN, LUM, AND VCAN), structural proteins (COL1A1), matricellular proteins (FBLN1, FBLN2,SMOC1), and matrix-modifying enzymes (LOX, LOXL1), CXCL14 | Found mainly in normal tissues or early tumors, Resident fibroblasts, involved in ECM production, regulates tumor immune response | (27) |
|                    | Cycling CAFs (cCAFs) | Similar to vCAFs but have differentially expressed cell cycle genes | Majority cells were in G2, M or S phase of cell cycle unlike others which are in G1 phase | (27) |
| Breast and lung cancer | Developmental CAFs (dCAFs) | stem cell genes (SCRG1, SOX9, AND SOX10), | Originated from malignant cells undergone EMT, involved in differentiation, development, and morphogenesis | (27) |
| PDAC | CD10⁺ GPR77⁺ CAFs | CD10, GPR77 | Chemoresistance, poor survival | (34) |
|                    | LRRC15⁺ CAFs | leucine-rich repeat-containing 15 (LRRC15), PDPN | TGF-β driven cell population, high expression is associated with poor anti-PD-L1 therapy response | (28) |
### TABLE 2 | Molecular profiling of endothelial cell heterogeneity in tumor human/mouse tissue samples.

| Endothelial cell phenotype | Transcriptional profiling | Major functions/activated signaling pathways | References |
|---------------------------|---------------------------|---------------------------------------------|------------|
| Tip cells                 | ESM1, APLN, ADM, MMP14, ANGPTL2, INSR, PDGFB, CXCR4, PGF, KCNE3, DLL4, RAMP3, EDNRB, LXN, CD34 | Cytoskeleton remodeling, involved in VEGF signaling, EC migration, extracellular matrix formation, collagen production | (30, 46, 47) |
| Stalk cells               | VWF, SELP, ACKR1, SPINT2, VEGFR2 | Known to originate from tip cells, maintains endothelial cell polarity, lumen formation | (47, 48) |
| Lymphatic ECs (LECs) and subtypes | LVE1, CCL21, TFF3, MMRN1, ADRF, AKAP12, FABP4, CD9, ANXA2, SNCQ, GYPC, S100A10, VIM, PPFIBP1, EFEMP1, PROX1, PDKN | Secrete SEMA4C promoting metastasis | (46, 49) |
| Tip cells                 | ESM1, APLN, ADM, MMP14, ANGPTL2, INSR, PDGFB, CXCR4, PGF, KCNE3, DLL4, RAMP3, EDNRB, LXN, CD34 | Cytoskeleton remodeling, involved in VEGF signaling, EC migration, extracellular matrix formation, collagen production | (30, 46, 47) |
| Stalk cells               | VWF, SELP, ACKR1, SPINT2, VEGFR2 | Known to originate from tip cells, maintains endothelial cell polarity, lumen formation | (47, 48) |
| Lymphatic ECs (LECs) and subtypes | LVE1, CCL21, TFF3, MMRN1, ADRF, AKAP12, FABP4, CD9, ANXA2, SNCQ, GYPC, S100A10, VIM, PPFIBP1, EFEMP1, PROX1, PDKN | Secrete SEMA4C promoting metastasis | (46, 49) |
| Tip cells                 | ESM1, APLN, ADM, MMP14, ANGPTL2, INSR, PDGFB, CXCR4, PGF, KCNE3, DLL4, RAMP3, EDNRB, LXN, CD34 | Cytoskeleton remodeling, involved in VEGF signaling, EC migration, extracellular matrix formation, collagen production | (30, 46, 47) |
| Stalk cells               | VWF, SELP, ACKR1, SPINT2, VEGFR2 | Known to originate from tip cells, maintains endothelial cell polarity, lumen formation | (47, 48) |
| Lymphatic ECs (LECs) and subtypes | LVE1, CCL21, TFF3, MMRN1, ADRF, AKAP12, FABP4, CD9, ANXA2, SNCQ, GYPC, S100A10, VIM, PPFIBP1, EFEMP1, PROX1, PDKN | Secrete SEMA4C promoting metastasis | (46, 49) |

**References**

(30, 46, 47)
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), angiopoietins (Ang), hepatocyte growth factor (HGF), hypoxia-inducible factor (HIF), insulin-like growth factor (IGF), transforming growth factor-beta (TGFβ), matrix metalloproteinase (MMP), and tumor necrosis factor (TNF) (54). Blood vessels built of TECs have loose interconnecting tight junctions, irregularly shaped, tortuous with high interstitial pressure, and ill-organized. TEC release pro-angiogenic factors such as VEGF, PDGF-β, FGF, and EGF show chromosomal abnormalities and are resistant to anticancer drugs (55). TEC derived cadherin-2 induces HIF-1α/VEGF mediated angiogenesis by regulating MAPK/ERK and MAPK/JNK signaling pathways (56).

**Non-coding RNAs Regulation in Tumor Angiogenesis**

Controlling vascular inflammation and angiogenesis is a limiting step to control tumor metastasis. Activation of tumor endothelial cells involves a cascade of events involving regulation by non-coding RNAs. They regulate transcriptional factors and governance mechanisms of neighboring genes. Various miRNAs are long known to regulate angiogenesis in tumor microenvironment. A comprehensive overview of pro-angiogenic and anti-angiogenic miRNAs is given in Table 3. LncRNA acts as molecular decoys of RNA binding proteins and are known to regulate protein-coding genes via interaction with transcriptional factors and other binding proteins (65). MVIH was the first lncRNA known that accounts for tumor angiogenesis in hepatocellular carcinoma (66). LncRNA regulate angiogenesis by activating oncogenic signaling pathways like NF-κB, STAT-3, AKT, mTOR, WNT. Man and co-workers reported a set of endothelial cells enriched with lncRNAs and identified the role of spliced-transcript endothelial-enriched lncRNA (STEEl) in angiogenic potential, macrovascular/microvascular identity, and shear stress responsiveness (67). STEEL upregulates eNOS and transcription factor Kruppel-like factor 2 (KLF2) in endothelial cells. Some of the other known lncRNAs include MALAT1, MANTIS, PUNISHER, MEG3, MIAT, SENGCR, GATA6-AS, WTAPP1, CCDS7, PVT1, CamK-A, UBE2CP3, HULC, OR3A4, LINC01410 each having specific roles in tumor angiogenesis (68). Wang and co-workers recently discovered a lncRNA named HITT (HIF-1α inhibitor at translation level) that is down-regulated in multiple human cancers (69). In hypoxic conditions, miR-205 upregulation causes HITT degradation and that allows YB-1 (Y-box binding protein) translational regulator binding on 5′UTR HIF-1α mRNA region leading to tumor angiogenesis. circRNA is another group of lncRNAs regulating angiogenesis (69). Multiple circRNAs act as miRNA sponges and regulate the mRNA expression of targeted angiogenic and vascular sequences. Yang and co-workers identified an inhibitory role of forkhead DNA-binding protein-Foxo3 circRNA on tumor growth and angiogenesis. circFoxo3 binds to miR-22, miR-136, miR-138, miR-149, miR-433, miR-762, miR-3614–5p, miR-3622b–5p and promotes translation of Foxo3 mRNA, which is a tumor suppressor gene (70). Similarly, circ_0003575, circ_0003204, circ_002136, and circ_001971/miR-29c-3p plays an important role in angiogenesis (71–73), circ_001621/miR-578 regulates VEGF/HIF-1α axis controlling breast cancer angiogenesis (74), circ_0007059/miR-378 regulates EMT transition in lung cancer cells (75). Also, long

| miRNAs               | Targeted signaling pathways | References |
|---------------------|----------------------------|------------|
| Proangiogenic       |                            |            |
| miR-9, miR-21, miR-874, miR-16, miR-34a, miR-590-5p, miR-132, miR-296, miR-210, miR-568, miR-23-5p, miR-150, miR-499 | VEGF signaling | (57–59) |
| miR-210, miR-155, miR-21, miR-200c, miR-199 | HIF signaling | (57, 58, 60, 61) |
| miR-375, miR-296, miR-146a | PDGF | (57, 62) |
| miR-126, miR-382, miR-29a, miR-145 | RTK signaling | (57, 62) |
| miR-9, miR-26-3p, miR-146a-5p, miR-98, miR-181a-5p | MMP signaling | (57, 62) |
| miR-503             | FGF signaling             | (57, 62) |
| miR-204             | Angiopoietin              | (60, 61) |
| miR-494             | Akt/eNOS pathway          | (60, 61) |
| miR-93              | Integrin-β                | (63)       |
| Anti-angiogenic      |                            |            |
| miR-15a, miR-16, miR-29b, miR-29c, miR-128, miR-497, miR-126, miR-503, miR-204, miR-195, miR-124, miR-138, miR-134, miR-107, miR-206, miR-622 | HIF signaling | (57, 61, 62) |
| miR-519c, miR-22, miR-107, miR-204, miR-128, miR-145, miR-206 | VE-cadherin | (57, 62) |
| miR-125b            | PDGF                     | (57, 62) |
| miR-29b, miR-204, miR-200c | RTK signaling | (60, 61) |
| miR-21, miR-218, miR-18a, miR-145 | MMP signaling | (57, 62) |
| miR-29b             | FGF signaling             | (57, 62) |
| miR-503, miR-148b-3p | Angiopoietin             | (57, 62) |
| miR-542-3p, miR-543 | Akt/eNOS pathway          | (60, 61) |
| miR-206             | VEGF signaling            | (57, 59, 61, 62) |

| Pro/Anti-angiogenic  |                            |            |
| miR-27b             | VEGF, AMPK, Semaphorin 6A | (67, 62, 64) |
| miR-17–92           | HIF-1α, VEGF              |            |
| miR-19a             | MMPs, VEGF                |            |
intergenic non-coding RNA-p21 (lincRNA-p21) is regulated by TP53 and angiogenesis-related genes (76).

**IMMUNE LANDSCAPE**

Immune cells are prime in TME that initially guards the body but eventually turns into a tumor supporting population (10). Both myeloid and lymphoid lineage have pro-tumoral and anti-tumoral roles depending upon the stage of cancer. For instance, macrophages promote T cells’ activation to clear tumor cells at early stages but prevent T cells from even recognizing the tumor cells as a tumor progresses (41). Immune cells communicate among each other and regulate mechanisms linked to tissue homeostasis and altered patient survival. Secretions from immune cells also shape the activity within TME. The secretion of CCL5 and XCL1 from NK cells attract antigen-presenting dendritic cells. IFNγ secretion promotes macrophage polarization and Th1 cell activation that triggers the immune microenvironment against tumor cells (77). In response, tumor cells secrete factors such as pro-inflammatory cytokines like IL8 and CXCL-1, 2, 8 that attract neutrophils. Neutrophils produce neutrophil extracellular traps (NETs) that shield the tumor cells from cytotoxic CD8+ T cells, NK cells, and minimize the effect of immunotherapies (78). Therefore, growing tumors are continuously combating the body’s immunity, which they eventually defeat. Immune cells are highly complex and consist of several distinct lineages that make them hard to study and target (79). Recognizing each immune cell’s indispensable role in supporting tumor proliferation, it would help us curb immunosuppressive reactions and promote immuno-stimulatory functions. scRNA-seq is a high-throughput approach that analyses the immune cells that typically display diverse phenotypes in-vivo (80). It identifies transcriptomics at single cell level by applying data processing pipelines including demultiplexing, sequence QC, alignment, and transcript quantification (81).

**MONOCYTES AND MACROPHAGES ARE PHENOTYPIC MARKERS OF AGGRESSIVE TUMORS**

Monocytes/macrophages are the major components of the tumor ecosystem (23). Human monocytes are divided into 3 largest clusters: classical (CD14++, CD16−), intermediate (CD14+CD16+), and non-classical (CD14−CD16++) (82). Recent mass cytometry (CyTOF) and single-cell studies have identified new monocyteic markers in tumor cells: CD68, CSF1-R, CSF2-R, CD11C, CD1C, CD141, and HLA-DR surface markers (83). A subset of monocytes expressing angiopoietin receptor TIE2 play a significant role in tumor angiogenesis. TIE2 monocytes are CD54+ CD11b+ CD16+ CD14low L-selectin-CCR2− and its expression is upregulated in response to hypoxia (84). Monocytes uniquely differentiate into immunosuppressive macrophages rather than into immunostimulatory DCs stimulated by the tumor secretions (85). Macrophages differ from monocytes by having a unique set of markers (D68, MSR1, MRC1) (44). Monocytes are recruited to the TME by chemotactants like CCL2, CCL4 which further differentiate into TAMs. Conventionally, macrophages are divided into two major groups CD14+ S100A8/9+ M1-like (classical macrophages) having anti-tumor functions and CD16+ (FCGR3A) M2-like (alternate macrophages) with pro-tumorigenic phenotypes (86). The percentage of TAM infiltration is a marker of aggressive disease and poor prognosis (87). Thorsson and colleagues characterized the dominance of monocytes/M2 macrophages associated with the worst prognosis while evaluating the immunogenomic signature in around 33 cancer types (88). M2 macrophages shows aggressive tumor phenotype associated with tumor growth, angiogenesis, immune evasion and cancer stemness. It also support mutagenic microenvironment and cancer initiation by producing pro-inflammatory cytokines (IL6, TNF-α, IFN-γ), growth factors (VEGF, EGF), proteases and reactive oxygen species (30). Tumor tissues are enriched in recruited macrophages known as mo-Macs that are ontogenically different from resident macrophages and are both anti and pro-inflammatory (30). The macrophage population varies spatially depending upon its location in growing tumors (tumor and juxta-tumoral regions), and tissue specificity. Tumor-specific subtypes as revealed by single-cell technology include early immigrant macrophages (HLA-DR+CD192+), monocyte resembling immature macrophages (CCR2+), tissue-resident macrophages (CD206+HLA-DR+), TAMs (CD64+HLA-DR+), and myeloid-derived suppressor cells (MDSC; HLA-DR−low) (19, 44) (Figure 2). Quin and co-workers precisely identified the types of M2 type macrophages in heterogeneous tumor microenvironment based on gene expression: PPARG+ macrophages exclusive to normal lung tissue, CCL18+ macrophages cluster and GPNMB, MMP9+ cluster having a role on tumor remodeling, CX3CR1+ cluster involved in pathogen and apoptotic cell clearance (44). The recent subtype identification by Qian and colleagues demonstrated the role of macrophages in tumor progression, promoting angiogenesis and invasion, and suppressing T cell responses (44). Many reports have also indicated the presence of PD-L1 in pro and anti-inflammatory markers (19, 89). PD-L1 TAMs are phenotypically heterogeneous and express CD38, pro-tumor markers CD204, CD206, CD169, and CD163, and the anti-tumor marker CD169 (19). Some monocyte and macrophage subsets are mentioned in Table 3.

**Regulation of TAM Phenotype by Non-Coding RNAs**

TAMs association with immunosuppressive and tumor supporting M2 phenotype necessitates TAM reprogramming that would act inversely and help cure tumors. The potential ability of TAM reprogramming towards antitumor phenotypes largely depends upon transcriptional control. There are a set of miRNAs involved in alternative macrophage activation: miR-9, miR-21, miR-375, miR-340-5p, miR-125a, miR-511, miR-92a, miR146a, miR-147, miR-145-5p, miR155, miR-187 (90, 91). The functional and biological relevance of IncRNAs is in the
initial phase of research. RP11-361F15.2 is a protumoral lncRNA that promotes M2-like polarization of TAMs by inversely regulating miR-30c-5p and plays a vital role in cancer invasion (92).

Similarly, BCRT1 is an M2 polarizing lncRNA that is upregulated in response to tumor hypoxia and leads to breast cancer progression via novel HIF-1α/lncRNA BCRT1/miR-1303/PTBP3 pathway (93). LncRNA RPPH1 mediates protumoral macrophage polarization by upregulating anti-inflammatory cytokines and also leads to colorectal cancer migration and metastasis by preventing β-III tubulin (TUBB3) ubiquitination (94). Many lncRNAs are known (NEAT1, TUC339, MM2P, MALAT1, ANCR), and many are still in research (95–97). CircRNAs also have regulatory functions but, not much is known about the role of circRNA in macrophage polarization as it relatively new field and holds promises in future therapeutics. Such discoveries would help us to understand precision medicine, some can be a biomarker depending upon

**FIGURE 2** | Immune landscape in early and late tumors. (A) Early tumors consist of non-aggressive hemopoietic cells such as classical monocytes, M0 macrophages, M1 pro-inflammatory/anti-tumor macrophages, NK1 and NK2 natural killer cell subtypes, conventional dendritic cells, naïve T cells, Follicular B cells. (B) As the tumor progresses to advanced stages, multiple immune cells converge to support pro-tumorigenic/anti-tumorigenic functions. Tumor-derived factors such as TGF-β, PGE2, interleukins, etc. are responsible for the diversification of immune cell types during cancer development. Moreover, with an increase in hypoxic and inflammatory core sites and activation of angiogenic switches, immune cells alter their conventional anti-tumorigenic behavior to pro-tumorigenic potential. (C) Monocyte subtypes, especially classical CD14+, Non-classical CD16+, TIE2+ cells, and intermediate cells, are present in late tumors. Hypoxia is a well-defined factor that leads to the regulation and infiltration of these monocytes into TME. (D) Types of macrophages present in late tumors: M2 (pro-tumorigenic) is the massively distributed subtype in late tumors and is related to poor prognosis and patient survival. They secrete a plethora of pro-tumorigenic proteases, cytokines and growth factors (for example, VEGF, EGF, which participates in a paracrine signaling loop through tumor-secreted CSF-1). The number of M1 macrophages are less in late tumors but comparatively higher in early tumors as they are anti-tumorigenic. MDSCs (myeloid-derived suppressor cells) are the recently discovered heterogeneous group of immune cells that are immunosuppressive. (E) Types of different neutrophils present in late tumors: majorly 5 types of neutrophils are known which are evolutionarily categorized from two subsets i.e., pro-tumorigenic and anti-tumorigenic. (F) Subtypes of T cells that play a role in shaping tumor immunity: helper, cytotoxic and effector memory T cells fight against growing tumors directly or indirectly by antigen presentation, cytotoxic granzyme and perforin release, cytotoxic T cells upon exhaustion are termed as exhaustive T cells and are signature of aggressive tumors, regulatory T cells are immunosuppressive, therefore linked with poor patient survival, gdT cells are a significant focus of cancer immunotherapy as they have strong cytokine production ability. (G) Types of B cells found in late-stage tumors, their antibody-secreting skills are linked with prolonged patient survival. But regulatory B cells are immunosuppressive. (H) Natural killer (NK) cells shaping tumor immunity; these are the cytotoxic cells and express a specialized class of natural cytotoxicity receptors (NCRs) such as NKp30, NKp44, and NKp46 which initiate tumor targeting by recognition of heparan sulphate on cancer cells. (I) Different types of dendritic cells (DCs) present in late-stage tumors: these are the active cells and express co-stimulatory molecules having efficient anti-tumor immune responses.
its abundance in a particular tumor, and some can be a great therapeutic tool.

**T CELL INTERACTOME WITHIN TME**

The complexity of tumor-infiltrating T cells suggests a strong influence of tumors on the T cell transcriptome. T cell population is generally sorted from the rest of the immune cells by CD3+CD4+CD8+CD25+ cell surface markers (98). They are classified conventionally as Naïve, effector, and memory T cells. In a specific study by Lambrechts and co-workers on NSCLC, single-cell sequencing reveals T cells clusters into regulatory T cells (FOXP3+), natural killer and natural killer T cells (FGFBP2+), CD8+ T cells (CD8+, naïve, effector, resident memory or exhausted), CD4+ T cells (CD4+), and minor populations of γδ T cells (23) (Figure 2). Following infiltration, naïve T cells differentiate into effector T cells that further activate into cytotoxic or central memory T cells (99). Primary tumors are enriched mainly with effector T cell subtypes characterized by high expression of chemokine receptors and cytotoxic genes like CD28, ICOS, OX40, CD40L, and CD137 and show low expression of exhausted T cell population (89). With tumor progression from primary to metastatic sites, expression of co-inhibitory receptors CTLA-4, PD-1, TIGIT, LAG3, TIM-3, and CD160 leads to progressive T cell dysfunctioning (89). Percentage of programmed cell death protein 1 (PD-1+), mucin domain protein 3 (TIM-3+), and cytotoxic T lymphocyte antigen-4 (CTLA-4+) cytotoxic and regulatory T cells increases in juxtumoral tissues. Cells expressing these co-inhibitory receptors are immunosuppressive, they originate from various sources influenced by TME; by migration from circulatory systems, effector T cell conversion, differentiation resulting from the suppression of APCs, etc (100). These suppress the NK cell activity, cytotoxic T cell response; thus, performing pro-tumoral functions (100). According to Qian and colleagues, some of the T cell clusters express NK cell markers (KLRL1, FGFBP2, CX3CR1), suggesting they are endowed with NK T-cell (NKT) activity (44). Currently, known T cell subtypes, marker profiling, and associated roles in TME are highlighted in Table 3.

**Regulation of T-Cell Function by Non-Coding RNAs**

T cells are at an extremely exhaustive stage in advanced tumors and require regulatory or transcriptional boosting to fight tumors. Non-coding RNAs regulating the T cell differentiation functions, harnessing T cell survival activities would be beneficial as therapies. miR-155 epigenetically silences the CD8+ T cell differentiation by enhancing Polycomb repressor complex 2 (PRC2) activity that blocks the transcription factors (EOMES, ID2, PRDM1, ZEB2, MAF, NR4A2) which are known to drive terminal differentiation and exhaustion (101). miR-28 is down-regulated in around 30% exhaustive T cell population. It can be an important therapeutic target as it inhibits the expression of the immune checkpoint molecules PD-1, TIM3 thus preventing exhaustive T cell differentiation (102). miR-16, miR-21, miR-142-3p, miR-142-5p, miR-150, miR-15b, miR-181a, and let-7f miRNAs are over-expressed in naïve T cells, and their expression reduces significantly in effector T cells (103, 104). Furthermore, miR-17-92, miR-21, miR-155, and miR-132-3p are over-expressed in effector and memory T cells compared to naïve T cells (103). Min and colleagues searched for miRNAs involved in DC differentiation to Treg cells and found the novel role of miR-27a in T cell differentiation. miR-27a is known to hamper Th1 and Th17 cell differentiation and help in the DC-mediated Treg (CD4+CD25+Foxp3+) population differentiation via pro-inflammatory cytokine production (105). Hence it is a potential target for cancer immunotherapy. Xu and co-workers demonstrate the role of miR-424 (322) in regulating the PD-L1/CD80/CTLA-4 axis in chemo-resistant ovarian cancer. miR-424 (322) restoration leads to PD-L1 blockade and activation of CD8+ T cells, thus preventing chemo-resistance inversely correlated with PDL1, PD1, CTLA-4 expression (106). The role of lncRNAs and circRNAs in T cell function is less explored area of research. Kotzin and colleagues discovered the role of lncRNA Mirr122b in CD8+ T cell differentiation in response to IFNγ viral infection (107). This lncRNA may have some role in tumor T cells as well but needs confirmation. Wang and co-workers discovered circRNA-002178 acting as a “competing endogenous RNA” (ceRNA) to promote PDL1/ PD1 expression in lung adenocarcinoma. circRNA-002178 could enhance PDL1 expression via sponging miR-34 in cancer cells to induce T-cell exhaustion (108). Thus circRNA-002178 reversal therapies may work against tumor supporting T cell population.

**B CELL TRANSCRIPTOME IN TME**

B cells are adaptive immune cells associated with prolonged patient survival (109). They are infiltrated within TME via CXCL13 secretions or antigens from tumor cells (110). B cells are relatively abundant in tumor samples compared to non-tumor (30) and are comparatively sparse compared to T cells in TME (111). B cells have five differentiated states: follicular B cells expressing CD20 (MS4A1), CXC4R, HLA-DRs, plasma B cells expressing immunoglobulin gamma (IgG) (MZB1 and SDC1/CD138), mucosa-associated lymphoid tissue-derived plasma B cells expressing IgA (CD38+), granzyme B-secreting B cells, and germinal center (GC) B cells (23). Individually, follicular B cells include mature-naïve (IGHM, CD72, CD27−) B cells that gives rise to memory B cells (IGHG1 and CD27+) while migrating through the germinal center (GC) (30). Some B cells have CD27− memory B-cell phenotype and express antigens associated with antigen-presenting cells (APCs) (namely, MHC class II, CD40, CD80, and CD86) (112). B cells residing in TME are exhaustive compared to ones in the non-tumorigenic environment as indicated by reduced protein secretion, and impairment of Myc and mTOR pathways (23). Mature-naïve B cells differentiate to IgM+ GC memory cells that further produce IgM- cells by undergoing a class-switch recombination mechanism. These IgM- and IgM+ cells finally produce GC
dependent memory B cells or plasma cells. IgM-memory B cells differentiate into either IgG+ or IgA+-expressing plasma cells (44) (Figure 2). Takemori and co-workers also identified a distinct class of memory B cells that are not matured in GCs but are a response to T cell antigens (113). Expression markers of B cell subtypes are mentioned in Table 3. B cells promote antitumor immunity by driving antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, complement activation, T cell activation, stimulating cytotoxic immune responses, and releasing granzyme B and TRAIL factors (114). B cell also have immunosuppressive pro-tumorigenic subsets such as regulatory B cell (CD1d+CD5+CD19+, CD5+CD19+) and CD5+ B cells (115). They are known to modulate the secretion of immunomodulatory cytokines such as IL10 and TGF-β.

B Cell Development and Activation by NON-CODING RNAs

miRNAs have a significant role in B cell development, activation, malignant transformation, and functions. There are some well-known miRNAs regulating B cell differentiation, proliferation and activation: miR15a, miR21, mir29, mir-17/92 cluster, miR-23a, miR-34a, miR-142, miR-150, miR-155, miR-181 family, miR-181a1b1, miR-212/125 cluster, miR-9, miR-17/92 cluster, miR-30, miR-125b, miR-155, miR-181b, miR-210, miR-221, miR-223, miR-148a, miR-146a (117, 118). miRNA 15A and 16-1 activate signaling pathways that mediate chemotaxis of immune regulatory B cells to colorectal tumors (119). IncRNAs are classified into six functional groups based on the functional chromatin features: eRNAs, promoter IncRNAs, bivalent IncRNAs, repressive IncRNAs, CTCF IncRNAs, and other IncRNAs (120). Zhou and co-workers discovered five B-cell-specific IncRNAs computationally (TNRC6C-AS1, WASIR2, GUSBP11, OGFRP1, and AC090515.2) associated with improved prognosis, and three B cell specific IncRNAs (PART1, MAFG-DT, and LINC01184) associated with poor prognosis in bladder cancer (121). Pyfrom and colleagues studied B cell-specific IncRNA BCALM (AC099524.1) highly expressed in various cancers. AC099524.1 is necessary for the interaction of signal transduction proteins PLD1 and AKAP9 and have implications in B cell immune response (122). Various other IncRNAs are known to have a role in B cell development: LEF-AS1, MYB-AS1, CRNDE, and SMAS-AS1 (123). The role of circRNA in tumor B cell activation is not yet explored.

NK CELLS AND OTHER DENDRITIC CELLS

Natural killer cells belong to an innate lymphoid family having cytotoxic and cytokine-producing potential and can identify tumor cells with the help of a unique set of receptors. NK cells are distinct from the rest of the immune cell population by having distinct cell surface markers CD3-/CD56+ or CD3−CD16+. They are majorly divided into different subpopulations depending upon CD16 and CD56 markers’ expression, each with distinct phenotypic properties (124). The presence of NK cells in tumors depends upon the stages and the cancer types. Tumor-specific NK cells exhibit high expression of CD69 and NKP44 activation markers and low expression of NKP30, NKP80, DNAM-1, CD16, and ILT2 as compared to peripheral blood and normal lung NK cells (125). Some NK cells strongly correlate with T cells and are popularly known as Natural Killer T (NK-T) cells (Figure 2). Dendritic cells are of multiple specialized subtypes (mentioned in Table 4) present in TME that are important for antigen presentation, phagocytosis, and adaptive immune responses. The historical origin of dendritic cells is through lymphoid lineage. The differentiating markers of DCs from the rest of the immune cells are HLADDR+ lineage-cells. Previously known DC subtypes include CD11c+ (Itga13) conventional DCs (cDCs) that are further characterized into either CD141+ or CD1C+ cells, and CD123+ (Bst2, Siglec) plasmacytoid DCs (pDCs) (82). Qin and colleagues identified five different DC subtypes in heterogeneous TME including conventional DCs (cDC1: CLEC9A, XCR1, BAFF3; cDC2: CD11b, CD1C, CLEC10A, SIRPA; cDC3 which include migratory DCs and expresses CCR7, CCL17, CCL19 gene expression, cDC4: pDCs expressing LILRA4, CXCR3, IRF7, and CDC5 expressing CD207 and Langerhans cell-specific markers) (44). Davidson and co-workers further classified dendritic cells based on their presence in tumors or lymph nodes (LN). Tumor cDC1 clusters express the dermal DC marker Cdl03 (Itgae), whereas the LN population expresses CD8α marker specific to LN resident dendritic populations (18). Transcriptionally, tumor DCs are more active and display a wider expression of different co-stimulatory molecules but lack T cell provoking stimulations than their counterparts.

Non-Coding RNAs Regulating NK and Dendritic Cell Functions

Non-coding RNAs play significant roles in the development, maturation, and effector functions of NK cells. They directly or indirectly control the cytotoxic ability and surface expression of immune checkpoints on NK cells, thus indicating their use in antitumor therapies (128). Zhu and co-workers concluded the regulatory effect of miR-20a, which is over-expressed in various cancers. miR-20a reduces the killing-effect of NK cells to cervical cancer cells by directly targeting RUNX1 (129). Similarly, overexpression of multiple miRNAs can inhibit the cytotoxic effect of NK cells: miR-24 suppresses IFN-γ and TNF-α and thus, affecting the killing-effect of NK cells (130). miR-218-5p reduces the NK cell activity by directly targeting IL-2 secretion in lung adenocarcinoma (131). Moreover, NK cells release exosomal RNA miR-3607-3p, acting as drug targets on pancreatic cancer cells. miR-3607-3p enriched in extracellular vesicles (EVs) derived from NK cells inhibits the malignant transformation of pancreatic cancer by targeting IL-26 (132). miR-150 and miR-203 increase tumor suppression; miR-155, miR-26a/b, miR-101, miR-363, etc. lead to decreased cell survival, cell cycle progression and miR-183 and miR-1245 are known to hamper NK killing activity in TME (128). Ou and colleagues elucidated the role of miR-153 and circ_0009777 in hypoxic...
### TABLE 4 | Distinct subsets of immune cells in human/mouse tumor tissues.

**Myeloid lineage**

| Cell type | Subtypes | Expression markers | Significance/Functions | References |
|-----------|----------|--------------------|------------------------|------------|
| Monocytes | Classical | CD14++, CD16-, FCN1 | Phagocytosis, innate sensing/immune responses and migration | (56, 79, 83, 84) |
|           | Non-classical | CD14+, CD16++, CDKN1C, LILRB2, ITGAL | Present antigen processing capabilities, promote neutrophil adhesion at the endothelial interface via the secretion of TNF-α | (84) |
|           | Intermediate | CD14++, CD16+, S100A8, S100A9, CSF3R, CCR5 | Express antigen presentation-related molecules, secrete TNF-α, IL-1β, IL-6, and CCL3 upon TLR stimulation | Not known |
|           | MonoDC | CLEC10A, MHC class II genes, CD74 | Tumor angiogenesis | Not known |
|           | TEMs | Tie2/TEK angiopeptin receptors | Proinflammatory/antitumorigenic, polarize to M2 type in advance stage cancers | Not known |
|           | Classical (M1) | CD14+ S100A8/9+ | Promote immunosuppression, support formation of abnormal vessels in TME that lead to tumor progression | Not known |
|           | Alternate/anti-inflammatory/protumorigenic (M2) | HLA-DR<low> | Immunosuppressive activities, promote tumor cell survival, angiogenesis | Not known |
| Monocytes | Myeloid-derived suppressor cells (MDSC) | | | |
| Neutrophils | Human | CD16+/FCGR3A, CD204, CD206, CD163 | | |
|           | Mouse | | | |
| Mast cells | Mast 1 | DAGLB, LTC4S, ALPI, KIT and MS4A2 | Involved in pro-tumoral and antimetastatic functions, release cytokines: IL-1α, IL-6, MCP-3, MCP-4, TNF-α, IFN-γ, LTβ4, TGFβ, IL-8, VEGF, FCγ2, NGF, heparin, tryptase | (79) |
|           | Mast 2 | CMA1, CTSG, ADCYAP1, MRC, HPGD, Fuz, MAPK6 | | |
| Lymphoid lineage | | | | |
| T cell | Helper T cells | CD4+ | Anti-tumor response | (18, 19, 44, 89) |
|           | Cytotoxic T cells | CD3+, CD8+, PDCD1 | Antitumor cells, express IFNγ, Prf1/perforin, granzyme B | (89) |
|           | Regulatory T cells | CD4+, FOXP3, IL2RA, CD25, CTLA-4, ENTPD1 (CD39) | Immunosuppressive cells | |
|           | Effector Memory T cells | CD4+, CD8+, CD197+, CD45RA- | Shows signs of dysfunction at later cancer stages, characteristic of advanced-stage tumors, anti-PD1 therapy response | |
|           | Exhaustive T cells | CD4+, CD8+, TIM-3, CTLA-4, HLA-DR, CD38 | Cytotoxic lymphocyte, express IL17 | |
**TME. circ_0000977** is overexpressed in pancreatic cancer and acts as a miR-153 sponge. It encourages hypoxia-mediated immune suppression by hampering NK mediated cell lysis (133). IncRNA GAS5 regulates NK cells cytotoxicity, tumor cell apoptosis, and tumor aggressiveness via miR-544/RUNX in liver cancer (134).

**CELLS SHAPING IMMUNOTHERAPIES**

Therapeutic strategies against different cancers are advancing in drug targets and carrier agents, keeping in mind the toxicity levels and patient response. In addition to conventional therapies such as radiotherapy and chemotherapy, immunotherapy is progressing to find new immune activation and protection methods. Different forms of immunotherapy are known: cancer vaccines, cytokine therapies, adoptive cell transfer, immune checkpoint inhibitors, T/NK-cell engineering, chimeric antigen receptor (CAR) T-cell therapy, and oncolytic virus therapies (135). Advancements in single-cell heterogeneity and identification of stromal/immune cell subtypes would provide new hopes in immunotherapy as it will identify new cell receptors to targets.

**Fibroblasts as Therapeutic Agents**

Diversity in CAF subtypes enlightens their immune-supportive and immune-suppressive functions via extensive studies of gene expression and metabolomic analysis. Targeting only the αSMA+ tumor population would not be helpful as it may result in the loss of immuno-supportive residents and may hamper significant homeostatic functions (136). But the presence of both types of the population indicates reprogramming between these two states. There is a particular need for targets that may reduce the reprogramming of fibroblasts to immune-suppressive subtypes. Targeting the immunosuppressive CAF population that promotes T cell differentiation to CD25+FOXP3+ cells and enhancing Tregs’ capacity to inhibit the proliferation of effector T cells would be an effective therapy. Remodeling these CAF subsets (CD29+ FAP++ FSP1+ αSMA++ PDGFRβ++ CA1− DPP4+) found in aggressive cancers would directly affect T cell immunity and leads to increased CD4+ CD25+ T lymphocyte survival (33). Ford and co-workers targeted a ROS-producing enzyme NOX4 to inhibit fibroblast differentiation to CAF and found high infiltration of NK cells and CD8+ T cell to tumors, and subsequent killing of cancer cells (137). Chen and colleagues explored the relation of fibrotic TME with T cell immunotherapy. Fibrotic TME indicates poor survival and suppresses the immune response to cancer (138). Anti-FAP antibodies (sibrotuzumab), TGF-β1 (highly expressed in hypoxic tumors), cytokine therapies (IL2), CXCL12/CXCR4 signaling, angiotensin receptor blockers (ARBs), immune checkpoint blockade (ICB), T lymphocyte checkpoint inhibition, CTLA-4 directed therapy, CAR-T cells against FAP+ cells are some of the immunotherapies currently in research to target non-responsive metastatic tumors (139, 140).

**TABLE 4 | Continued**

| Myeloid lineage | Cell type | Subtypes | Expression markers | Significance/functions |
|-----------------|-----------|----------|-------------------|-----------------------|
| B cell          | Follicular B cells | CD20 (MS4A1), CXCR4, HLA-DR | Gives rise to naïve/memory B cells (44, 114) |
|                 | Naïve B cells | CD27-; IGHD+(IgD)/IGHM+(IgM) | Gives rise to other B cell types |
|                 | Memory/Effector B cells | CD27+, Granzyme B, TRAIL, MHC I, MHC II, IFN, IL-12 | Direct tumor cell killing, antigen presentation, macrophage polarization, CD4+ T cell conversion, recruitment of osteoclasts, and conversion of CD69+ cells to Treg promote immunosuppressive, convert CD4+ T cells to CD25+ T cells |
|                 | Plasma B cells | MZB1, SDC1/CD138, PRDM1, CD20 | Antibody secreting cells, opsonization, complement system activation, antibody-dependent cellular cytotoxicity (ADCC), antibody-mediated phagocytosis, antigen presentation by dendritic cells, and drive cytotoxic T cell responses |
|                 | Mucosa-associated IgA+ B cells | IgA+, CD20−/CD19+ | Immunosuppressive, convert CD4+ T cells to Treg, promote angiogenesis, macrophage polarization, MSC development |
|                 | Germinal center B cells | CCR7, GPR183, IGHM | Undergoes class switch recombination to form other immunoglobin subtypes |
|                 | Regulatory B cells | PD-1, TAC-CD198, OX40, perforin++ | Immunosuppressive, express inhibitory ligands and cytokines, inhibit T cell and NK cell response |
|                 | NK cell | CD56− | Mediates natural and antibody-dependent cellular cytotoxicity, exhibiting high levels of perforin and enhanced killing (89, 127) |
|                 | CD56+ | CD56, NKG2A, CD27, KIR | NK-T cells |
|                 | CD9, CXCR3 | CD56+, CD16low | Anti-tumorigenic in early tumor stages, show immunosuppressive activity |
|                 | CD69+ | CD56, NKG2A, CD27, KIR | Antitumorigenic in late-stage tumors |
|                 | CD8− | CD69+ | CD56+, CD16low | NK-T cells |
|                 | CD8+ | CD9, CXCR3 | Anti-tumorigenic in early tumor stages, show immunosuppressive activity |
|                 | CD16+ | CD56, NKG2A, CD27, KIR | Antitumorigenic in late-stage tumors |
|                 | CD16+ | CD56+, CD16low | CD56+, perforinlow |
|                 | CD8− | CD69+ | CD56+, CD16low | CD56+, perforinlow |
|                 | CD8+ | CD69− | CD56+, CD16low | CD56+, perforinlow |
|                 | CD8− | CD69+ | CD56+, CD16low | CD56+, perforinlow |
|                 | CD8+ | CD69− | CD56+, CD16low | CD56+, perforinlow |
Therapeutic Aspects of Tumor Angiogenesis

Tumor cells communicate with nearby endothelial cells that line-up in angiogenic vessels and safeguard the growing tumors. Approaches to block vascular supply are long under investigation and have reached the bedside but with limited efficacy, low response rate, high resistance, and enhanced immune surveillance (141). Ongoing anti-angiogenic treatments include anti-VEGF therapies (bevacizumab), tyrosine kinase inhibitors (Sunitinib), targeting signals between cells (Revlimid), and chemotherapy combination with numerous side-effects. Decreasing tumor’s blood supply also leads to hypoxia, fuelling tumor progression, and metastasis. As an alternative therapy, vascular normalization encourages improved blood flow and reduced tumor hypoxia, understanding vascular normalization, and implementation are still in research (142). Vascular targeting would directly or indirectly enhance tumor immunity. Tumor vasculature functionality depends on the interaction with M1/M2 like TAMs, CD4+/CD8+ T cells, and other stromal/immune cells. Mpekris and co-workers highlighted the combined use of immune checkpoint and anti-angiogenetic antibodies for more favorable outcomes (143). Targeting endothelial cells (EC) subtypes is comparatively a new field and is yet to explore to find out novel anti-angiogenic candidates. Currently, combination drugs are in clinical trials that target both immune checkpoint blockades (ICBs) and angiogenesis such as Atezolizumab + bevacizumab + entinostat/Avelumab + axitinib/Atezolizumab + bevacizumab + carboplatin + pemetrexed (144).

TAMs Targeted Therapies

TAMs are the most targeted population for immunotherapy as they constitute a major cellular component of TME. With the expansion in macrophage research, the complex phenotypic and functional properties of macrophages have unveiled their recruitment processes, polarization signals, differentiation factors, etc. Cassetta and co-workers identified 37-gene TAM signature highlighting CSF-1 and SIGLEC1 (a sialic binding receptor) mainly expressed by macrophages in aggressive human breast cancer subtypes (87). High CSF-1 and SIGLEC1 receptors in macrophages indicate tumor progression, poor clinical prognosis, and can be targeted a therapeutic option (145). Currently, TAM targeted therapies involve macrophage depletion, receptor targeting (Tyro3, Axl, and MerTK), effector functions inhibition, reprogramming towards antitumor phenotype, and inhibiting recruitment within TME. Still, all of these therapies are limited to identifying TAM-specific markers (10). Many macrophage targeted drugs are under clinical investigations: monoclonal antibodies targeting CSF-1R (IMC-CS4, R05509554, RG7155, FPA008, PLX3397) and CCL2 (Carlumab), small molecule inhibitors, antibodies targeting reprogramming strategies (anti-CD47, anti-CD40), toll-like receptor agonists, PI3Kγ inhibitors, inhibition of microRNA activity, histone deacetylase inhibitors (TMP195), anti-CD4-1 and CTLA4 therapies to name a few. Each of these strategies needs careful investigations as they have certain limitations and require practicing new approaches as underpinned by current knowledge of macrophage biology.

T Cell and B Cell Immunotherapy

T cell therapeutics is advancing since the discovery of a breakthrough of chimeric antigen receptor (CAR) -modified T cells and immune modulation using antibodies that block immune regulatory checkpoints in 2013. Both CD8+ and CD4+ cells have multifaceted roles in antitumor immunity. CD4+ cells secrete interleukin (IL)-2 activating CD8+ T cells, cytokine secretion (IFN-γ, TNF-α), activation of CD40 ligands that activates dendritic cells and leads to differentiation and maturation of B cells (146). Immune checkpoint blockade (ICB), adoptive cell transfer (ACT), and engineering TCR therapy are some primary T cell-based therapies currently in clinical trials. ICB involves the use of antibodies to neutralize inhibitory receptors CTLA-1, PD-L1/B7-H1/CD274, lymphocyte-activation protein 3 (LAG-3), T-cell immunoglobulin, mucin-domain containing-3 (TIM-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (147). The role of B cells in immune protection is currently in research. Besides producing antibodies, B cells have crucial roles in immune regulation or functions as an antigen-presenting cell, but involvement in cellular therapy is unclear, despite having numerous effector functions. Recently Helming and co-workers identified differentially expressed B cell markers (MZB1, JCHAIN, and IGLL5) in ICBs responders relative to non-responders indicating the driving force of B cells in immunotherapy (148).

Therapies Involving NK Cells

NK cells can induce direct killing of tumor cells, and recruit or activate of T cells and DCs. Three forms of NK therapy have emerged: Bi-specific antibodies, induction of antibody-dependent cell-mediated cytotoxicity (ADCC), and gene therapy with NK cells. Current possibilities to use NK cells are (a) targeting inhibitory NK cell surface receptors or (b) targeting activating NK cell receptors (149). NKG2A is a novel heterodimeric (expressed along with CD94) intracytoplasmic tyrosine-based inhibitory motif (ITIM) expressed on both T and NK cells and recognizes human leukocyte antigen (HLA)-E present on tumor cells (150). Binding of NKG2A/CD94 to its cognate ligand inhibits T and NK cell effector functions and thus are immunosuppressive. Andrea and co-workers developed a humanized anti-NKG2A immunoglobulin G (IgG) 4-blocking mAb (monalizumab) and showed that NKG2A blockade activates NK and CD8+ T cells (150). Another possibility is targeting activating NK cell receptors such as natural killer group 2D (NKG2D), CD16, signaling lymphocyte activation molecule (SLAM)-family members, and the natural cytotoxicity receptors (NCRs) Nkp30, Nkp44, and Nkp46 (151). CD16 in tumor conditions binds to EGFR and leads to tumor cell proliferation. Antibody such as cetuximab and trastuzumab inhibits EGFR signaling and binds to CD16 to promote ADCC. Moreover, many tumors are consistent with a high frequency of Nkp46 receptors. Targeting this receptor would help in the activation of other NK cell receptors that lead to cytokine release and the
killing of tumor cells. Gauthier and co-workers developed a multifunctional antibody (NKp46 specific) targeting CD19, CD20, or EGFR as tumor antigens and triggering tumor killing by NK cells (151, 152). CD73 is another immune checkpoint that defines regulatory NK cells within TME. CD73 is associated with immune suppression and tumor progression involving CD4+ T cell suppression (153). Developing future therapies CD73 would be beneficial for T cell functioning and tumor regression.

CONCLUSIONS

Research in the field of the tumor microenvironment is an impressive and significant stage. Despite progress in cancer immunotherapies, the incidence of tumor relapse and recurrence had necessitated a profound study of tumor heterogeneity. Clinically we are struggling with therapies that would target a wide range of cells, being unaware of subtypes that escape and show resistance. Many drugs target tumor biome by using monoclonal antibodies, angiogenic, and protein kinase inhibitors, but the precise targets are rare. With advances in single-cell technology, intra-tumoral heterogeneity is not much explored. Characterization of stromal and immune cell subtypes inhabiting at different tumor stages, early or late-stage, and the corresponding normal tissues revealed a broad range of cell subsets, differentiation patterns, and immunological regulations within TME. Targeting these well-explored immuno-modulatory cells directs the development of next-generation therapeutics. These next-generation therapies are at an early stage of development and would involve trials on small molecule inhibitors, non-coding RNAs, and cell-specific receptors that may lead to better cancer cure.

FUTURE PERSPECTIVES

There are still several questions in the TME that needs careful investigation. One aspect is the lineage tracing. A challenge in tumor biology is associating molecular differences among progenitor cells and their capacity to generate differentiated cell types. Studies are needed to associate changes in progenitor and mature cell types and answer questions such as a) Does a differentiated cell have the capability to transdifferentiate in other differentiated cell types in TME? If yes, what are these cells in the tumor microenvironment that shows cellular plasticity? b), and how the cellular plasticity is regulated? To answer these questions, we need to understand the origin of stromal or immune cell types in TME.

The second aspect is understanding the heterogeneity of stromal and immune cells that make up most of the TME. Fibroblasts and macrophages are among the most diversified populations whose characteristics change with their location in tumors- perivascular, hypoxic, necrotic areas, and regions of interaction with blood vessels and lymph nodes. Rare information is available on the interaction of these cells with other cell types and how different tumor zones influence the development of subtypes. Technologies such as spatial transcriptomics (seqFISH, MERFISH, STARmap) and multiplex immunofluorescence would be pivotal to identify prevailing subtypes.

The third aspect requiring attention is tumor secreto. Investigations on exosomal secretions, non-coding RNA transcriptomics, and epigenetic remodeling would boost our understanding of tumor biome. Single-cell genomic technologies are an efficient approach to understand every subtype residing within TME. It can also enhance our ability to discover novel target molecules, specific pathways targeted by these drugs, that would facilitate effective strategies. Identification of precise sub-typical population by scRNAseq analysis can serve as biomarkers to develop accessory treatments. Assessment at a single cell level can also provide us cell variations before and after immunotherapies with which medications can be optimized. In summary, we anticipate that single-cell analysis would be a great approach to understand tumor biology and designing therapies that would revolutionize the tumor treatments as it may reduce the gap between responders and non-responders.

AUTHOR CONTRIBUTIONS

LA and DP contributed to the study conception and design. LA collected the relevant paper and drafted the manuscript. DP revised the manuscript and supervised the study. LA and DP prepared the review figures and tables of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by SERB women excellence award (SB/WEA-02/2017) to DP Also, DP gratefully acknowledges financial support of IIT Ropar to the TERM laboratory.

ACKNOWLEDGMENTS

LA acknowledges IIT Ropar and MHRD for her research fellowship.

REFERENCES

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet (1889) 1:571–3. doi: 10.1016/S0140-6736(00)49915-0
2. Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 9(6):394–408. doi: 10.2174/138920208785699580
3. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14:275–91. doi: 10.1016/j.stem.2014.02.006
4. Srivastava D, DeWitt N. In vivo cellular reprogramming: the next generation. Cell (2016) 166:1386–96. doi: 10.1016/j.cell.2016.08.055
5. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell (2008) 132:661–80. doi: 10.1016/j.cell.2008.02.008
6. Tata PR, Chow RD, Saladi SV, Tata A, Konkimalla A, Bara A, et al. Developmental history provides a roadmap for the emergence of tumor plasticity. Dev Cell (2018) 44:679–93.e5. doi: 10.1016/j.devcel.2018.02.024

7. Waddington CH. The Strategy of Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957). doi: 10.5694/j.1326-3777.1958.tb06509.x

8. Jopling C, Boue S, Izipisuia Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol (2011) 12:79–89. doi: 10.1038/nrm3043

9. Magnen CL, Shen MM, Abate-Shen C. Understanding tumor ecosystems by single-cell RNA-seq. RNA Biol (2015) 12:381–8. doi: 10.1080/15476286.2015.1020271

10. Bolisetty MT, Graveley BR. Circuitous route to transcription regulation. Mol Cell (2013) 51:705–6. doi: 10.1016/j.molcel.2013.09.012

11. Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Nat Rev Genet (2013) 14:13. doi: 10.1038/nrg3419

12. Ren X, Kang B, Zhang Z. Understanding tumor ecosystems by single-cell sequencing: promises and limitations. Genome Biol (2019) 19(1):211. doi: 10.1186/s13059-018-1593-z

13. Dominguez CX, Muller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into IRRIC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov (2020) 10(2):232–53. doi: 10.1158/2159-8290.CD-19-0644

14. Bolisetty MT, Graveley BR. Circuitous route to transcription regulation. Mol Cell (2013) 51:705–6. doi: 10.1016/j.molcel.2013.09.012

15. Schoberth JD, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Discrete Signalling Niches Regulate Cancer Progression and Metastasis. Nat Med (2013) 19:1423–37. doi: 10.1038/nm.3394

16. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Annu Rev Cancer Biol (2015) 2(3):a006536. doi: 10.1101/cshperspect.a006536

17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57–70. doi: 10.1016/s0092-8674(00)07163-6

18. Davidson S, Efremova M, Riedel A, Mahata B, Pramanik J, Huhlaten J, et al. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. Cell Rep (2020) 31(7):107628. doi: 10.1016/j.celrep.2020.107628

19. Wagner J, Rapsomanikis MA, Chevrier S, Anzeneder T, Langwieder C, Dygiers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell (2017) 175(5):1330–45.e18. doi: 10.1016/j.cell.2016.09.055

20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57–70. doi: 10.1016/s0092-8674(00)07163-6

21. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, et al. Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Discrete Signalling Niches Regulate Cancer Progression and Metastasis. Nat Med (2013) 19:1423–37. doi: 10.1038/nm.3394

22. Yofe I, Dahan R, Amit I. Single-cell genomic approaches for developing the next generation of immunotherapies. Nat Med (2020) 26(2):171–7. doi: 10.1038/s41591-019-0736-4

23. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer (2016) 16:582–98. doi: 10.1038/nrc.2016.73

24. Lambrecht D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al. Phenotype modeling of stromal cells in the lung tumor microenvironment. Nat Cell Biol (2018) 20(8):1277–89. doi: 10.1038/s41591-018-0096-5

25. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun (2017) 8:15081. doi: 10.1038/ncomms15081

26. Hanley CJ, Waise S, Parker R, MA L, Taylor J, Kimbley LM, et al. Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer. bioRxiv (2020), 134270. doi: 10.1101/2020.06.08.134270

27. Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Sommarin M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun (2018) 9(1):5150. doi: 10.1038/s41467-018-07582-3

28. Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-Cell RNA Sequencing Reveals Stromal Evolution into IRRIC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discov (2020) 10(2):232–53. doi: 10.1158/2159-8290.CD-19-0644

29. Elyada E, Bolisetty M, Laise P, Flynn WF, Courtot ET, Burkhart RA, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov (2019) 9(8):1102–23. doi: 10.1158/2159-8290.CD-19-0094

30. Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun (2020) 11:2285. doi: 10.1038/s41467-020-16164-1

31. Fletcher AL, Acton SE, Knoblich J. Lymphe node fibroblastic reticular cells in health and disease. Nat Rev Immunol (2015) 15(6):350–61. doi: 10.1038/nri3846

32. Barlow CJ, Waise S, Parker R, MA L, Taylor J, Kimbley LM, et al. Spatially discrete signalling niches regulate cancer progression and metastasis. Annu Rev Cancer Biol (2018) 2(3):a006536. doi: 10.1101/cshperspect.a006536

33. Waddington CH. The Strategy of Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957). doi: 10.5694/j.1326-3777.1958.tb06509.x

34. Waddington CH. The Strategy of Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957). doi: 10.5694/j.1326-3777.1958.tb06509.x

35. Waddington CH. The Strategy of Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957). doi: 10.5694/j.1326-3777.1958.tb06509.x

36. Waddington CH. The Strategy of Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957). doi: 10.5694/j.1326-3777.1958.tb06509.x

37. Waddington CH. The Strategy of Genes: A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957). doi: 10.5694/j.1326-3777.1958.tb06509.x
Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of small noncoding microRNAs in Tumor Angiogenesis and Clinical Implications. _J Exp Clin Cancer Res_ (2020) 39(1):91. doi: 10.1016/j.jccr.2020.01709-5

Orso F, Quirico L, Dettori D, Coppo R, Virga F, Ferreira LC, et al. Role of microRNAs in tumor and endothelial cell interactions during tumor progression. _Semin Cancer Biol_ (2019) 60:214–24. doi: 10.1016/j.semcancer.2019.07.024

Wang X, Wang L, Chen C, Chu X. New Insights into the Regulatory Role of microRNA in Tumor Angiogenesis and Clinical Implications. _Mol Cancer_ (2018) 17:222. doi: 10.1186/s12943-018-0376-6

Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. _Cancer Cell_ (2008) 14(5):382–93. doi: 10.1016/j.cccr.2008.10.005

Kong W, He L, Richards EJ, Challas S, Xu CX, Permutt-Wey J, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. _Cancer Res_ (2014) 74(15):3919–28. doi: 10.1158/0008-5472.CAN-13-3136

Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microRNA in Tumor Angiogenesis and Clinical Implications. _J Exp Clin Cancer Res_ (2020) 39:204. doi: 10.1186/s12943-017-0376-6

Goradel NH, Mohammadi N, Hagh-Aminjan F, Farhood B, Nagahdari B, Sahekbar A. Regulation of tumor angiogenesis by microRNAs: State of the art. _J Cell Physiol_ (2019) 234(2):1099–110. doi: 10.1002/jcp.27051

Fang L, Deng Z, Shateva T, Yang J, Peng C, Du WW, et al. MicroRNA mir-93 promotes tumor growth and angiogenesis by targeting integrin-β3. _OncoGnc_ (2011) 30:806–21. doi: 10.1002/onc.2010.465

Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, et al. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. _PLoS One_ (2013) 8(4):e60687. doi: 10.1371/journal.pone.0060687

Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. _Cell_ (2018) 172(3):393–407. doi: 10.1016/j.cell.2018.01.011

Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. _Hepatology_ (2012) 56(6):2231–41. doi: 10.1002/hep.25895

Man HSJ, Sukumar AN, Lam GC, Turgeon PJ, Yan MS, Ku KH, et al. Angiogenic patterning by STEEL, an endothelial-enriched long noncoding RNA. _Proc Natl Acad Sci U S A_ (2018) 115:2401–6. doi: 10.1073/pnas.1715182115

Yu B, Wang S. Angio-LncRs: LncRNAs that regulate angiogenesis and vascular disease. _Theranostics_ (2018) 8(13):3654–75. doi: 10.7150/thno.26024

Wang X, Li L, Zhao K, Lin Q, Li H, Xue X, et al. A Novel LncRNA HITT Forms a Regulatory Loop with HIF-1α to Modulate Angiogenesis and Tumor Growth. _Cell Death Differ_ (2020) 27:1431–46. doi: 10.1038/s41418-019-0449-8

Yang W, Du WW, Li X, Yee A, Yang BB. Fxox3 activity promoted by non-coding effects of circular RNA and Fxox3 pseudogene in the inhibition of tumor growth and angiogenesis. _OncoGene_ (2016) 35(30):3919–31. doi: 10.1038/oncc.2015.48

Li CY, Ma L, Yu B. Circular RNA has_circ_0003575 regulates oxLDL-induced vascular endothelial cells proliferation and angiogenesis. _BioMed Pharmacother_ (2017) 95:1514–9. doi: 10.1016/j.biopha.2017.09.064

Liu H, Ma X, Mao Z, Liu H, Shen M, Zhu J, et al. Circular RNA has_circ_0003240 inhibits oxLDL-induced vascular endothelial cell proliferation and angiogenesis. _Cell Signal_ (2020) 70:109595. doi: 10.1016/j.cellsig.2020.109595

Chen C, Huang Z, Mo X, Song Y, Li X, Li X, et al. The circular RNA 001971-miR-29c-3p axis modulates colorectal cancer growth, metastasis, and angiogenesis through VEGFA. _J Exp Clin Cancer Res_ (2020) 39(1):91. doi: 10.1186/s13046-019-0159-2

Ji X, Shan L, Shen P, He M. Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression. _Cell Death Dis_ (2020) 11(11):18. doi: 10.1038/s41419-019-2204-y

Gao S, Yu Y, Liu L, Meng J, Li G. Circular RNA has_circ_0007059 restrains proliferation and epithelial-mesenchymal transition in lung cancer cells via inhibiting microRNA-378. _Life Sci_ (2019) 233:116692. doi: 10.1016/j.lfs.2019.116692

Castellano JJ, Navarro A, Vinolas N, Marrades RM, Moises J, Cordeiro A, et al. LincRNA-p21 Impacts Prognosis in Resected Non-Small Cell Lung Cancer Patients through Angiogenesis Regulation. _J Thorac Oncol_ (2016) 11(12):2173–82. doi: 10.1016/j.jtho.2016.07.015

Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. _Nat Rev Drug Discov_ (2020) 19(3):200–18. doi: 10.1038/s41573-019-0052-1

Teijeira A, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, et al. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. _Immunity_ (2020) 52(5):856–71.e8. doi: 10.1016/j.immuni.2020.03.001

Zilionis R, Engblom C, Pfirsich C, Savova V, Zemmor D, Satcioglu HD, et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. _Immunity_ (2019) 50(5):1317–34.e10. doi: 10.1016/j.immuni.2019.03.009

Chen H, Ye F, Guo G. Revolutionizing immunology with single-cell RNA sequencing. _Cell Mol Immunol_ (2019) 16(3):242–9. doi: 10.1038/s41423-019-01224-4

Gao M, Ling M, Tang X, Wang S, Xiao X, Qiao Y, et al. Comparison of high-throughput single-cell RNA sequencing data processing pipelines. _Briefings Bioinf_ (2020) bkb0116. doi: 10.1093/bib/bkb0116

Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. _Science_ (2017) 356(6335):eaax4573. doi: 10.1126/science.aax4573

Kapellos TS, Bonaguro L, Gemünd I, Reusch N, Saglam A, Hinkley ER, et al. Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. _Front Immunol_ (2019) 10:2035. doi: 10.3389/fimmu.2019.02035

Devalaraja S, To TKJ, Folkert JW, Natesan R, Alam Z, Li M, et al. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression. _Cell_ (2020) 180(6):1098–114.e16. doi: 10.1016/j.cell.2020.02.042
86. Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. *Arterioscler Thromb Vasc Biol* (2013) 33(7):1478–83. doi: 10.1161/ATVBAHA.113.300168

87. Casetta L, Fragkoigianni S, Sims AH, Swierzczak A, Forrester LM, Zhang H, et al. Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. *Cancer Cell* (2019) 35(4):588–602.e10. doi: 10.1016/j.ccell.2019.02.009

88. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. Single-Cell Map of Dividing Immune Phenotypes in the Breast Tumor Microenvironment. *Cell* (2018) 174(5):1293–308.e16. doi: 10.1016/j.cell.2018.05.060

89. Azizi E, Carr AJ, Pitts G, Cornish AE, Konopacki C, Prabhakaran S, et al. UCA1 Regulates PRL-3 Expression by Sponging MicroRNA-495 to Promote CD8+ T cell aging. *Nat Commun* (2020) 11:3819. doi: 10.1038/s41467-020-2230-9

90. Curtale G, Rubino M, Locati M. MicroRNAs as Molecular Switches in Macrophage Activation. *Front Immunol* (2019) 10:799. doi: 10.3389/fimmu.2019.00799

91. Towner DM, Etscheidt M, De Palma M, Pettet MJ. MicroRNA-mediated control of macrophages and its implications for cancer. *Trends Immunol* (2013) 34:350–9. doi: 10.1016/j.it.2013.02.003

92. Wang Y, Liu K, Fan L, Li X, Jiang W, et al. LncRNA RP11-30eC3.2 promotes osteosarcoma tumorigenesis by inhibiting miR-21. *Oncogene* (2019) 39(10):1296–304. doi: 10.1038/s41388-019-0425-x

93. Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. *Mol Cancer* (2020) 19(1):85. doi: 10.1186/s12943-020-01206-5

94. Li X, Lei Y, Wu M, Li N. Regulation of Macrophage Activation and Polarization by HCC-Derived Exosomal lncRNA TUC339. *Int J Mol Sci* (2018) 19:2958. doi: 10.3390/ijms1902958

95. Yi C, Xiong JB, Zhang GY, Liu Y, Jie ZG, Li ZR, et al. Long Noncoding RNA Expression during Human B-Cell Development. *Int J Mol Sci* (2016) 17:307. doi: 10.3390/ijms17030306

96. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 12(11):749–61. doi: 10.1038/nri3307

97. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Speciﬁc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* (2004) 10:942–9. doi: 10.1038/nm1093

98. Li Y, Fieravanti J, Zha W, Wang H, Wu T, Hu J, et al. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate. Nat Commun (2019) 10:2157. doi: 10.1038/s41467-019-09882-8

99. Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424(322) reverses chemoresistance via T cell immune response activation by blocking the PD-L1 immune checkpoint. *Nat Commun* (2016) 7:11406. doi: 10.1038/ncomms11406

100. Kotzin JJ, Isaka F, Wright J, Basavappa MG, Clark ML, Ali MA, et al. The long noncoding RNA Morbid regulates CD8+ T cells in response to viral infection. *Proc Natl Acad Sci U S A* (2019) 116(24):11916–25. doi: 10.1073/pnas.1819457116

101. Min S, Li L, Zhang M, Zhang Y, Liang X, Xie Y, et al. TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7. *Genes Immun* (2012) 13:621–31. doi: 10.1038/gene.2012.45

102. Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D, et al. miR-28-3p regulates CD8+ T cell fate by direct interaction with PD-L1. *Front Immunol* (2019) 10:821. doi: 10.3389/fimmu.2019.01387

103. Cui G, McMichael AJ, Mcgovern P, Davis MD. B cells, plasma cells and antibody repertoires in the tumour microenvironment. *Nat Rev Immunol* (2020) 20(5):294–307. doi: 10.1038/s41577-019-0257-x

104. Bentzon M, Ishii H, Zhang Z, Le K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. *Clin Cancer Res* (2012) 18:3281–92. doi: 10.1158/1078-0433.CCR-12-0234

105. Takemori T, Kaji T, Takahashi Y, Shimoda M, Rajewsky K. Generation of memory B cells inside and outside germinal centers. *Eur J Immunol* (2014) 44:1258–64. doi: 10.1002/eji.201343716

106. Zhang C, Xin H, Zhang W, Yazaki PJ, Watson PH, et al. Promoting exosomes-mediated macrophage M2 polarization. *Cell Death Dis* (2019) 10:892. doi: 10.1038/s41419-019-2077-0

107. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Chudakov DM, Bottai G, Raschioni C, Calin GA, Santarpia L. Targeting miR-1303/PTBP3 axis. *Mol Cancer* (2020) 19(1):85. doi: 10.1186/s12943-020-01206-5

108. Dong J, Qiao J, Li B, Wang J, et al. Molecular Switches in Macrophage Activation. *Front Immunol* (2019) 10:821. doi: 10.3389/fimmu.2019.01387

109. Varn FS, Mullins DW, Arias-Pulido H, Fiering S, Cheng C. Adaptive immune programmes in breast cancer. *Immunology* (2015) 160(1):25–34. doi: 10.1111/imn.12664

110. Liu S, Wang L, Ly D, Xu H, Qi L, Zhang L, et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. *Cell Mol Immunol* (2019) 16:6–18. doi: 10.1016/j.cmi.2019.08.008

111. Schoorl R, Riviere AB, Borne AE, Felkamp-Vroom TM. Identification of T and B lymphocytes in human breast cancer with immunohistochemical techniques. *Therapeutic Targets. Landscapes Reveal Cancer-Specific* (2016) 7:11406. doi: 10.1038/ncomms11406

112. Nielsen JS, Sahota RA, Milne K, Cost SE, Nesslinger NJ, Watson PH, et al. miR-424−3p promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage polarization. *Cell Death Dis* (2019) 10:892. doi: 10.1038/s41419-019-2077-0

113. Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et al. miR-424(322) reverses chemoresistance via T cell immune response activation by blocking the PD-L1 immune checkpoint. *Nat Commun* (2016) 7:11406. doi: 10.1038/ncomms11406

114. Kotzin JJ, Isaka F, Wright J, Basavappa MG, Clark ML, Ali MA, et al. The long noncoding RNA Morbid regulates CD8+ T cells in response to viral infection. *Proc Natl Acad Sci U S A* (2019) 116(24):11916–25. doi: 10.1073/pnas.1819457116

115. Wang J, Zhao X, Wang Y, Ren F, Sun D, Yan Y, et al. circRNA-002178 acts as a ceRNA to promote PD-L1/PD1 expression in lung adenocarcinoma. *Cell Death Dis* (2020) 11:32. doi: 10.1038/s41419-020-2230-9

116. Arora and Pal Cell Diversity in Tumor Microenvironment
124. Poli A, Michel T, Thérésine M, Andrés E, Hengst F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. *Immunology* (2009) 126(4):458–65. doi: 10.1111/j.1365-2567.2008.03567.x

125. Cremer I, Fridman WH, Sauze-Fridman C. Tumor microenvironment in NSCLC suppresses NK cells function. *Oncoimmunology* (2012) 1:244–6. doi: 10.4161/oncn.1.2.18309

126. Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils. *Cancer Res* (2019) 80(9):1846–60. doi: 10.1158/0008-5472.CAN-19-3158

127. Stabile H, Fionda C, Ferretti E, Obino V, Carlomagno S, Rutigliani M, et al. miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. *Front Cell Dev Biol* (2020) 8:119. doi: 10.3389/fcell.2020.00119

128. Pesce S, Greppi M, Ferretti E, Obino V, Carlomagno S, Rutigliani M, et al. miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy. *Front Cell Dev Biol* (2020) 8(11):1592. doi: 10.3349/fmmu.2019.02819

129. Zhu SY, Wu QY, Zhang CX, Wang Q, Ling J, Huang XT, et al. miR-20a downregulating RUNX1. *Biochem Biophys Res Commun* (2018) 505(1):309–16. doi: 10.1016/j.bbrc.2018.09.102

130. Zhang LL, Zhang LF, Shi YB. miR-24 inhibits the killing effect of natural killer cells to cervical cancer cells by downregulating RUNX1. *Biochem Biophys Res Commun* (2018) 505(1):309–16. doi: 10.1016/j.bbrc.2018.09.102

131. Yang Q, Li J, Hu Y, Tang X, Yu L, Dong L, et al. MiR-20a inhibits the killing effect of natural killer cells to cervical cancer cells by downregulating RUNX1. *Biochem Biophys Res Commun* (2018) 505(1):309–16. doi: 10.1016/j.bbrc.2018.09.102

132. Sun H, Shi K, Qi K, Kong H, Zhang J, Dai S, et al. Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. *Front Immunol* (2019) 10:2819. doi: 10.3389/fimmu.2019.02819

133. Ou ZL, Luo Z, Wei W, Liang S, Gao TL, Lu YB. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis. *RNA Biol* (2019) 16(11):1592–603. doi: 10.1080/15476286.2019.1649585

134. Feng P, Xiang L, Chen W, Li S, Huang S, Li J, et al. IncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. *Innate Immun* (2019) 25(2):99–109. doi: 10.1177/17534259187632

135. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cell Mol Immunol* (2020) 17:807–21. doi: 10.1038/s41423-020-0488-6

136. Chauhan VP, Chen IX, Tong R, Ng MR, Martin JD, Naxerova K, et al. Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. *Proc Natl Acad Sci U S A* (2019) 116(22):10674–80. doi: 10.1073/pnas.1819899116

137. Ford K, Hanley CJ, Mellone M, Szynrdalewiez C, Heitz F, Wiesel P, et al. NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. *Cancer Res* (2020) 80(9):1846–60. doi: 10.1158/0008-5472.CAN-19-3158

138. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. *Nat Rev Drug Discov* (2019) 18(2):99–115. doi: 10.1038/s41573-018-0004-1

139. Lee J, Fassnacht M, Nair S, Boczkowski D, Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. *Cancer Res* (2005) 65(23):11156–63. doi: 10.1158/0008-5472.CAN-05-2805
# Glossary

| Abbreviation | Description |
|--------------|-------------|
| ACT          | adoptive cell transfer |
| ADCs         | adult stem cells |
| ADCC         | antibody-dependent cellular cytotoxicity |
| AKT          | activate protein kinase B |
| APCs         | antigen-presenting cells |
| apCAFs       | antigen-presenting CAFs |
| CAR-T cells  | chimeric antigen receptor T-cells |
| CAFs         | cancer-associated fibroblasts |
| COL1A1       | collagen type I alpha 1 |
| COL13A1      | collagen type III alpha 1 chain |
| COL14A1      | collagen type XIV alpha 1 chain |
| CCL5         | chemokine (C-C motif) ligand 5 |
| CSF          | colony-stimulating factor |
| CTLA-4       | cytotoxic T-lymphocyte-associated protein 4 |
| CXCL12       | C-X-C motif chemokine 12 |
| cyTOF        | time-of-flight mass spectrometry |
| DC           | dendritic cell |
| dCAFs        | developmental CAFs |
| DPP-4        | dipeptidyl peptidase-4 |
| EC           | endothelial cell |
| ECM          | extracellular matrix |
| EGF          | epidermal growth factor |
| eNOS         | endothelial nitric oxide synthase 3 |
| EMTs         | epithelial-mesenchymal transitions |
| ERK          | extracellular-signal-regulated kinase |
| eRNAs        | enhancer RNAs |
| ESCs         | embryonic stem cells |
| ESCC         | esophageal squamous cell carcinoma |
| FAP          | fibroblast activated protein |
| FGFR3A        | low affinity immunoglobulin gamma Fc-region receptor III-A |
| G0S          | fibroblast growth factors |
| FGFBP-2       | fibroblast growth factor binding protein 2 |
| FOXP3        | forkhead box P3 |
| GC           | germinal center |
| HIF-1alpha    | hypoxia-inducible factor 1-alpha |
| HITT         | inhibitor at translation level |
| HLA          | human leukocyte antigen |
| ICAMs        | inflammatory CAFs |
| Ig           | immunoglobulin |
| IGHG1        | immunoglobulin heavy constant gamma 1 |
| JNK          | c-Jun N-terminal kinase |
| KLF2         | Kruppel-like factor 2 |
| KLRD1        | Killer cell lectin-like receptor subfamily D, member 1 |
| LRRC15       | leucine-rich repeat containing 15 |
| lncRNAs      | long intergenic non-coding RNAs |
| ICB          | immune checkpoint blockade |
| IFN          | interferon |
| IL-6         | interleukin 6 |
| IL-11        | interleukin 11 |
| IL-1beta     | interleukin 1 beta |
| LAG3         | lymphocyte-activation gene 3 |
| LN           | lymph nodes |
| mAb          | monoclonal antibody |
| MALAT1       | metastasis-associated lung adenocarcinoma transcript 1 |
| MAPK         | mitogen-activated protein kinase |
| mCAFs        | matrix CAFs |
| MHCIi        | major histocompatibility complex class II |
| miRNAs       | MicroRNAs |
| MMP9         | matrix metalloproteinase 9 |
| MMTV-PyMT     | mouse mammary tumor virus-polyoma middle tumor-antigen |
| Morrbd       | myeloid RNA repressor of BCL2L11 induced death |
| MSCs         | mesenchymal stem cells |
| mTOR         | mammalian target of rapamycin |
| mTORs        | natural cytotoxicity receptors |
| NET1         | noncoding nuclear-enriched abundant transcript 1 |
| NF-kappaB     | nuclear factor kappa-light-chain-enhancer of activated B cells |
| NK           | natural killer |
| NKG2D        | natural killer group 2D |
| NOX4         | NADPH oxidase 4 |
| PDAC         | pancreatic ductal adenocarcinoma |
| pDC          | plasmacytoid DCs |
| PDGF         | platelet-derived growth factor |
| PD-L1        | programmed death-ligand 1 |
| pIRNAs       | Piwi-interacting RNAs |
| PROC2        | Polycomb repressor complex 2 |
| ROS          | reactive oxygen species |
| S100A4       | S100 Calcium Binding Protein A4 |
| scRNAseq     | Single-cell RNA sequencing |
| SIGLEC1      | siglec acid binding Ig like lectin 1 |
| siRNAs       | small interfering RNAs |
| SLAM         | signaling lymphocyte activation molecule |
| sno-lncRNAs  | Srrm-derived small lncRNAs |
| SOX-4        | SRY (sex determining region Y) box 4 |
| STAT3        | Signal transducer and activator of transcription 3 |
| STEEL        | spliced-transcript endothelial-enriched IncRNA |
| TAMs         | tumor-associated macrophages |
| TCR          | T cell receptor |
| TECs         | tumor endothelial cells |
| TGF-β1        | transforming growth factor beta 1 |
| TIGIT        | T cell immunoreceptor with Ig and ITIM domains |
| TIM-3        | T-cell immunoglobulin and mucin-domain containing-3 |
| TME          | tumor microenvironment |
| TNF-α        | tumor necrosis factor alpha |
| TRP5          | Tumor protein 53 |
| TRAIL         | TNF-related apoptosis-inducing ligand |
| Treg         | regulatory T cells |
| UTR          | untranslated region |
| VEGF         | vascular endothelial growth factor |
| vCAFs        | vascular CAFs |
| vWF          | von Willebrand factor |
| Wnt          | Wingless-related integration site |
| YB-1         | Y-box binding protein |
| ZEB1         | Zinc Finger E-Box Binding Homeobox 1 |

(Continued)